DK1432402T3 - Sammensætning til tilförsel af lægemiddelkombinationer - Google Patents

Sammensætning til tilförsel af lægemiddelkombinationer

Info

Publication number
DK1432402T3
DK1432402T3 DK02766997T DK02766997T DK1432402T3 DK 1432402 T3 DK1432402 T3 DK 1432402T3 DK 02766997 T DK02766997 T DK 02766997T DK 02766997 T DK02766997 T DK 02766997T DK 1432402 T3 DK1432402 T3 DK 1432402T3
Authority
DK
Denmark
Prior art keywords
administration
composition
drug combinations
combinations
antagonistic
Prior art date
Application number
DK02766997T
Other languages
Danish (da)
English (en)
Inventor
Paul Tardi
Troy Harasym
Murray Webb
Clifford Shew
Lawrence Mayer
Marcel Bally
Andrew Janoff
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002383259A external-priority patent/CA2383259A1/en
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1432402T3 publication Critical patent/DK1432402T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02766997T 2001-10-03 2002-10-03 Sammensætning til tilförsel af lægemiddelkombinationer DK1432402T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32667101P 2001-10-03 2001-10-03
US34152901P 2001-12-17 2001-12-17
US35675902P 2002-02-15 2002-02-15
CA002383259A CA2383259A1 (en) 2002-04-23 2002-04-23 Synergistic compositions
US40198402P 2002-08-07 2002-08-07
US40873302P 2002-09-06 2002-09-06
PCT/CA2002/001500 WO2003028696A2 (en) 2001-10-03 2002-10-03 Compositions for delivery of drug combinations

Publications (1)

Publication Number Publication Date
DK1432402T3 true DK1432402T3 (da) 2007-03-26

Family

ID=32475852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02766997T DK1432402T3 (da) 2001-10-03 2002-10-03 Sammensætning til tilförsel af lægemiddelkombinationer

Country Status (13)

Country Link
EP (2) EP1693052A1 (ja)
JP (2) JP4778679B2 (ja)
AT (1) ATE345775T1 (ja)
AU (1) AU2002331480B2 (ja)
CA (1) CA2462369C (ja)
CY (1) CY1105953T1 (ja)
DE (1) DE60216305T2 (ja)
DK (1) DK1432402T3 (ja)
ES (1) ES2272768T3 (ja)
HK (1) HK1065714A1 (ja)
IL (2) IL161214A (ja)
PT (1) PT1432402E (ja)
WO (1) WO2003028696A2 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
US20060193902A1 (en) * 2003-04-02 2006-08-31 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
ES2594621T3 (es) * 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
CA2574767C (en) 2004-07-19 2015-02-17 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
EP1796689A4 (en) * 2004-09-20 2009-01-14 British Columbia Cancer Agency GEMCITABINE FREE OR ENCAPSULATED IN LIPOSOMES ONLY OR IN ASSOCIATION WITH FREE IDARUBICIN OR ENCAPSULATED IN LIPOSOMES
CA2582949A1 (en) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
WO2008007113A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
EP1933813A4 (en) * 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER
AU2006306108B2 (en) * 2005-10-25 2012-10-04 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) * 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery
WO2009022190A1 (en) * 2007-08-16 2009-02-19 Biocompatibles Uk Limited Delivery of drug combinations
ES2535217T3 (es) 2007-11-28 2015-05-07 Celator Pharmaceuticals, Inc. Sistema mejorado de administración de taxano
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
EP2344161B1 (en) 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
WO2016145096A1 (en) 2015-03-09 2016-09-15 The Regents Of The University Of California Polymer-drug conjugates for combination anticancer therapy
MX2018000611A (es) * 2015-07-15 2018-09-06 Celator Pharmaceuticals Inc Sistemas mejorados de entrega de nanoparticula.
CN105434437B (zh) * 2015-12-01 2018-03-02 山东大学 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法
CN106619509B (zh) * 2016-12-21 2020-02-18 山东大学 一种奥沙利铂和伊立替康共载载药脂肪乳及其制备方法
US20230093147A1 (en) * 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL26210A (en) * 1965-08-02 1970-12-24 Merck & Co Inc Pharmaceutical compositions containing substituted sulphoxides
JP3213471B2 (ja) * 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
WO2000056361A2 (en) * 1999-03-24 2000-09-28 The Secretary Of State For Defence Vaccine composition
CA2369263A1 (en) * 1999-04-09 2000-10-19 Jessie Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
IL146872A0 (en) * 1999-06-03 2002-08-14 Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
HUP0202669A3 (en) * 1999-09-09 2004-06-28 Univ California Cationic liposome delivery of taxanes to angiogenic bloos vessels
EP1220657A1 (en) * 1999-10-14 2002-07-10 1170535 Ontario Inc. Liposome encapsulated silver salt compositions
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001058910A2 (en) * 2000-02-10 2001-08-16 Liplasome Pharma A/S Lipid-based drug delivery systems
AU2001249393A1 (en) * 2000-03-22 2001-10-03 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody

Also Published As

Publication number Publication date
JP2010180210A (ja) 2010-08-19
JP2005508920A (ja) 2005-04-07
DE60216305D1 (de) 2007-01-04
WO2003028696A2 (en) 2003-04-10
AU2002331480B2 (en) 2007-10-25
IL188774A0 (en) 2008-04-13
ATE345775T1 (de) 2006-12-15
JP4778679B2 (ja) 2011-09-21
EP1693052A1 (en) 2006-08-23
PT1432402E (pt) 2007-02-28
JP4926256B2 (ja) 2012-05-09
CY1105953T1 (el) 2011-04-06
IL161214A (en) 2008-06-05
WO2003028696A8 (en) 2006-09-08
ES2272768T3 (es) 2007-05-01
WO2003028696A3 (en) 2003-07-31
DE60216305T2 (de) 2007-07-05
EP1432402B1 (en) 2006-11-22
CA2462369C (en) 2009-12-22
EP1432402A2 (en) 2004-06-30
HK1065714A1 (en) 2005-03-04
CA2462369A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
DK1432402T3 (da) Sammensætning til tilförsel af lægemiddelkombinationer
WO2004093795A3 (en) Compositions for delivery of drug combinations
NZ527157A (en) Compositions for delivering bisphosphonates
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
ATE537844T1 (de) Dauerhafte lokalanästhetische zusammensetzung mit saib
GB0008269D0 (en) Combination chemotherapy
MX2007002189A (es) Sales de dicetopiperazina, sales de dicetomorfolina o sales de dicetodioxano para suministro de farmacos.
ATE538797T1 (de) Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
WO2009086400A3 (en) Recombinant vwf formulations
NO20026255D0 (no) Polymere micelle sammensetninger
WO2005112633A3 (en) Compounds and compositions for delivering active agents
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
TW200517106A (en) Sustained release pharmaceutical compositions
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
WO2007035783A3 (en) Combination formulations of cytidine analogs and platinum agents
BRPI0515344A (pt) composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2002015959A3 (en) Compounds and compositions for delivering active agents
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen